The EU's CHMP has endorsed the approval of Shire's Vpriv (velaglucerase alfa) for long-term enzyme replacement therapy (ERT) in patients with type 1 Gaucher's disease, the most prevalent type of the rare lysosomal storage disease.
Shire said that it aims to launch the drug as soon as possible. The opinion came early – it was expected during the autumn. Shire commented that the committee's positive...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?